Rare Disease Refresh: FDA’s Rare Disease Framework Initiative

FDA’s new Rare Disease Framework Initiative is a thoughtful, ambitious, and laudable effort to build a regulatory structure that systematically supports rare disease therapeutic development and review. Detailed in the October 2026 white paper, A New Framework for Rare Disease Review, the initiative is led by the Rare Disease Innovation Hub in partnership with the Office of the Commissioner, CDER, and CBER, with engagement from CDRH and other relevant offices.

Its central promise is to make fit-for-purpose evidentiary expectations the norm for rare disease applications. FDA intends to build a framework in which advice and decision-making are consistently tailored to the evidence reasonably attainable given the disease, its onset and progression, the patient population and its needs, and the investigational product – and clearly communicated throughout development and review.  We hope this means sponsor-FDA discussions will begin with an open consideration of the approaches appropriate to the disease and product, rather than presumptions favoring conventional development sequencing, randomized controlled trials, or traditional statistical thresholds that sponsors must then seek to rebut.

Building a Structure for Consistency

A longstanding concern for patients, developers, and those of us who advocate on their behalf is uncertainty about how FDA applies regulatory standards across review divisions, product centers, therapeutic modalities, and disease areas. HPM’s research has documented FDA’s use of tailored approaches over decades (see here), and we continue to highlight recent examples (see here). This initiative provides an opportunity to make that practice systematic across the Agency.

The initiative therefore seeks to go beyond articulating an approach. FDA proposes to examine policies, procedures, programs, guidance, regulations, and organizational practices to build a durable regulatory structure. Its scope extends from pre-IND engagement through post-approval obligations, includingwhat has become an increasing pain point in chemistry, manufacturing, and controls (CMC) and pre-approval inspections.

A central component is coordinating and consolidating rare disease review expertise across CDER and CBER, supported by shared resources, institutional knowledge, and training. In our view, this could represent a “Rare Disease Innovation Hub 2.0”: translating the experience of existing programs into a structure that consistently informs development advice and regulatory decisions across the Agency.  We hope the Hub can play a role in implementing that framework.

Of particular note, FDA states it will consider revisions to regulations to embed fit-for-purpose evidentiary standards into the foundation for rare disease review. Currently, FDA draws concepts of flexibility from the regulatory framework but relies on guidance, which is non-binding and subject to change, to define that flexibility. Regulations expressly establishing a tailored approach as the default could provide a more durable and predictable foundation for its consistent application.

Guidance and training would then translate that foundation into practice, with guidance better suited to address specific methodological considerations as science evolves. FDA anticipates systematically reviewing guidance and potentially issuing new or revised guidance addressing endpoints, statistical approaches, trial design, patient engagement, external expert consultation, and post-approval obligations, with training to support consistent implementation by reviewers.

From Case-by-Case Flexibility to Regulatory Certainty

The initiative reinforces an important distinction: tailoring the application of regulatory standards to rare disease circumstances preserves the statutory requirements for safety and effectiveness. FDA seeks to use scientific advances, innovative methods, disease expertise, and patient perspectives to identify evidence that can meet those requirements.

We have long championed appropriate flexibility in FDA’s application of the legal standards for approval. We have also raised concerns about the pressure that reliance on an imprecise concept of flexibility places on reviewers and leadership: it can leave FDA staff feeling that they are being asked to “color outside the lines.” A clearly articulated regulatory structure, reinforced through guidance and training, could provide a firmer foundation for applying those same standards to the realities of rare disease development.

If FDA achieves its goals of clarity, consistency, and predictability, appropriately flexible approaches could become a dependable default in rare disease development and review. That would provide greater regulatory certainty about how evidence should be generated and evaluated. Such certainty could encourage greater interest and investment in rare disease programs by making feasible development pathways easier to anticipate and pursue.

What Happens Next?

FDA plans a public meeting (to be held on October 28), a Federal Register request for information, sector-specific roundtables, and internal reviewer feedback sessions to inform the framework’s development. We commend this thoughtful approach to engage both external stakeholders, but also internally to ensure the framework incorporates the experiences and insights from review staff.

HPM’s perspective on that effort is informed by more than a quarter-century of engagement with the rare disease community, including service on the boards of the RARE Foundation (formerly the EveryLife Foundation for Rare Diseases), NORD, and IndoUSrare.  Our work has included involvement in more than one-third of new chemical entity approvals for rare conditions and more than half of accelerated approvals outside oncology, as well as organizing more than two-thirds of Externally-Led Patient-Focused Drug Development meetings. Across these efforts, we have seen the importance of bringing patient perspectives, disease expertise, and appropriately tailored evidentiary expectations into regulatory decision-making.

That experience reinforces our support for FDA’s commitment to build a structure that makes these practices systematic. We look forward to working with the Rare Disease Innovation Hub and its Director, Amy Rick, alongside patients, patient organizations, sponsors, researchers, investors, and other stakeholders to help establish a framework that provides greater regulatory certainty and advances the development of much-needed therapies.